Medtronic Resolute Drug-Eluting Stent Shows Strong Results, Even in Challenging Diabetes Patients with Coronary Disease

Currently under review by the U.S. Food and Drug Administration, the Resolute® drug-eluting stent (

) from Medtronic, Inc.

continues to demonstrate consistently positive performance across a variety of studies, according to two new data analyses being presented this week at TCT 2011. The first analysis, RESOLUTE Pooled Diabetics, focuses on outcomes in patients with both coronary artery disease and diabetes, two common comorbidities; the second, RESOLUTE Pooled Safety, focuses on safety outcomes across all patient types.